Currently available treatments for Alzheimer’s Disease (AD): such as reversible anticholinesterases namely tacrine, donepezil, rivastigmine, galantamine and NMDA receptor antagonists like memantine provide largely symptomatic relief with only minor effects on the course of the disease. Alzheimer's disease is a multifactorial, progressive neurodegenerative disorder with a poor prognosis, and thus, novel therapies for AD are certainly needed in a growing population of elderly patients or asymptomatic individuals, who are at risk for AD, worldwide. Most current Alzheimer's disease (AD) therapies in advanced phases of development target amyloid ?-peptide (A?) production, aggregation, or accumulation. Translational models suggest that anti-A? therapies may be highly effective if tested as agents to prevent or delay development of the disease or as therapies for asymptomatic patients with very early signs of AD pathology. However, anti-A? therapeutics are currently being tested in symptomatic patients where they are likely to be much less effective or ineffective.